Medarex-man kommt einfach nicht an Ihnen vorbei - 500 Beiträge pro Seite

[lilabaer]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[janolo]

Du hast ja Recht, rosaroterpanther.

Es stimmt schon, MEDX ist in den letzten Tagen schön langsam gestiegen.
Vielleicht kommt ja heute mal der große Sprung auf die 120 E.
Mit meinen "Träd" wollte ich nur sagen, daß diese Aktie manchmal ganz schön nervig sein kann. Ich bin selber spekulativ eingestellt und habe so manch andere noch spekulativere Werte im Depot. Von DAX-Werten halte ich nicht viel, höchsten den ein o.anderen OS-Schein drauf.
Zu MEDX muss ich sagen, daß die ein absolut solides und lohnendes Investment ist, auch wenns ab und an mal runter geht.
Ich denk` schon, daß demnächst mal ein größerer Sprung nach oben wieder drin ist.

Wie siehst Du das?

Bis die Tage,
janolo

[Skorpy]

Hy Freunde zuerst hatt sie mal die 100 geknackt
mal sehen wies weitergeht :-))))
Skorpy**

[Dauphin]

Yep!
Wenn die 100 $ nachhaltig überschritten werden, ist der Weg zu den ath`s frei!


MfG Dauphin

[IWA Japan]

[IWA Japan]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[lilabaer]

Ich glaube wir werden nächste Woche zum ersten Mal wieder die 110 sehen. Auch wenn es danach wieder etwas bergab gehen sollte, so steht doch eines fest: Die Entwicklung der letzten 3-4 Monate zeigt einen endeutigen Trend nach oben.
Medarex hat sich mit einigen weniger in den letzten Tagen gegen den negativen Sog standhaft gewehrt.
Natürlich versucht sich jeder, der investiert ist meist nur die positiven Seiten anzuschauen, aber ich glaube bei Medarex, da kann keiner dran vorbeigehen, es sei denn jemand sucht Verluste für seine Steuer GG
Schönes Wochenende noch,
Lilabaer

[Dauphin]

Hast Recht IWA

Es wird wohl aber noch dauern bis 110 $ sicher hinter uns liegen, da die Stochastic im überkauften Bereich ist.
MACD wiederum scheint noch in Ordnung zu sein, oder sehe ich da was falsch?

MfG Dauphin

[lilabaer]

hallo freunde von medarex,
den wochenanfang haben wir doch einigermaßen überstanden. die letzten waren ja schlimmer. aufgrund des negativ belasteten handels haben wir noch erfreuliche zahlen hingelegt. etwas besorgniserregend ist höchstens der nachbörsliche handel, aber da wurden wir ja schon oft eines besseren belehrt. die garazange ist auf jeden fall geknackt, daher können wir recht positiv in die woche schauen,
bis bald

[IWA Japan]

ist euich schon mal der Aufschlag von 25% von ABGX gegenüber MEDX aufgefallen (Stand letzen Freitag)

für mich unverständlich: 1. habe ich bereits mehrfach von Marktteilnehmern vernommen, dass MEDX noch etwas besser positioniert sei wie ABGX, somit also höher bewrtet sein müsste, auch in den versch. Kooperationen, die man als Außenstehender vielleicht nicht exakt in ihrer Werthaftigkeit bewerten kann, steht MEDX ABGX zumindest in nix nach.

Neben der besseren technologischen Postionierung spricht auch die Pipeline für MEDX: unabh. von den UMsatzpotentialen, deren Volumen man kaum erfährt bei diesen Werten, hat MEDX 5 Präparate in der kl. Entwicklung, davon 2x Phase II und 1x Phase III

ABGX bringt es nur auf 3 Präparate, wobei eines in 2 INdikationen getestet wird. MAcht also quasi 4.

Hierbei ist nur 1 in Phase II und 1 ins Phase III, allerdings im Gegensatz zu MEDX erst ganz am ANfang von Phase III, d.h. eine erste Marktzulassung erfolgt bei ABGX erst später als bei MEDX.


Fazit: eher müsste MEDX einen Aufschlag von 25% erhalten

[IWA Japan]

[money_max]

Interview with Medarex CEO Donald Drakeman by Todd Jerles of Team StreetSideInvestor

Good afternoon, this is Todd Jerles with StreetSideInvestor’s Executives’ Corner. Today we’re speaking with Dr. Donald Drakeman, Chief Executive Officer of Medarex. Medarex is a biotechnology company that is developing therapeutic products for life threatening and debilitating diseases based on proprietary technology in the field of monoclonal antibodies.

StreetSideInvestor: Please give our readers an overview of what it is Medarex actually does?
Dr. Drakeman: We use monoclonal antibody technology to turn genomic discoveries into new treatments for cancer and other life threatening and seriously debilitating diseases.
StreetSideInvestor: One of your most interesting and successful technologies is the HuMab-Mouse. What exactly is the "mouse," and how can it be used for medical gain?
Dr. Drakeman: Antibodies are the body’s first line of defense against disease. Unfortunately, our bodies don’t always make antibodies when they should. For example, cancer is a disease of your own cells, and the body is not good at making antibodies against cancer. We can make completely human antibodies against cancers and other diseases by using our HuMab-Mouse. This is a mouse that has been genetically engineered to have certain human genes instead of mouse genes. In particular, the mouse genes responsible for making antibodies have been knocked out, or eliminated, and they’ve been replaced by human genes for making antibodies. So, when a mouse responds to a cancer tissue that we put into the mouse, the mouse will make human antibodies like the ones you and I might make, and those antibodies can be used to treat human patients without any concern about the antibodies looking foreign or strange to the patients’ immune systems.
StreetSideInvestor: Please elaborate on the numerous corporate collaborations that Medarex maintains centering around the HuMab-Mouse technology, and do you expect any new partnerships to arise in the near future?
Dr. Drakeman: Because our technology is the fastest and the most efficient way to move from genomic discovery to new treatments for disease, our HuMab-Mice and other antibody technologies are very attractive to many, many companies in the pharmaceutical and biotech industries. Right now we have 22 corporate partners working with us on this technology including many of the largest pharmaceutical and biotech companies like Novartis, Johnson & Johnson, Bristol-Myers, Amgen, Immunex, and others. We are in the middle of discussions right now with a long list of potential partners, and we expect to be announcing additional partnerships in the near term, in the mid term, and the long term. This is a technology with a great deal of potential, and I think people are recognizing that and want to take advantage of it for their own product development programs.
StreetSideInvestor: How does your recently completed T-12 Development program serve to more quickly and cost-effectively bring drugs to clinical trial?
Dr. Drakeman: Traditionally it has taken the pharmaceutical industry 5-6 years and $20-30 million to move from having an interesting disease target to actually launching human clinical trials for a new therapeutic product to treat that disease. So the target-to-trial timeframe is quite a long time, taking 5-6 years. Our T-12 development program means target-to-trial in 12 months, and we have recently taken a fully human antibody from disease target to clinical trials in one year. This speed and efficiency allows us to take advantage of the new medical opportunities being presented by the genomic revolution in an unprecedented way, and that will allow both Medarex and our partners to develop new products faster than has been possible in the past.
StreetSideInvestor: What other technologies and products are currently in the works at Medarex, and what are the clinical statuses of these products?
Dr. Drakeman: We’ve been in the monoclonal antibody business for about 10 or 11 years now, and before the development of the fully human antibody technology, we were working with partially human antibodies which were the cutting-edge technology of the time. We have a number of products in clinical trials all the way from a Phase I, which is the first level of testing, to Phase III, which is the last clinical trial before filing with the FDA to begin commercial sales of the product. So we’re in a number of disease areas ranging from cancer to autoimmune disease and look for these products to be moving forward while we inaugurate a number of new trials each year for our new fully human antibodies.
StreetSideInvestor: At what point do you foresee Medarex achieving a profitable state?
Dr. Drakeman: The Wall Street analysts put those dates anywhere between 2 and 4 years from now. Our focus right now at Medarex is to make a significant investment in R&D so that when we become profitable, we become extremely profitable based on a broad pipeline of important new products.
StreetSideInvestor: Finally, if there was one thing you could leave with our readers to think about when Medarex comes to mind, what would it be?
Dr. Drakeman: Genomic discovery is changing medicine the way the Internet changed communications. Medarex is in the position to be the fastest and the most efficient developer of new genomic medicine thanks to its human antibody technology.


von www.streetsideinvestor.com

[money_max]

Genencor International erweitert seine Lizensen von Medarex

Genencor Obtains Key Rights for Immunology Platform Development - Licenses for i-mune(TM) Mouse Program -
PALO ALTO, Calif., Aug. 22 /PRNewswire/ -- Genencor International, Inc. (Nasdaq: GCOR - news) announced today that it has expanded the scope of its licenses from Medarex, Inc. (Nasdaq: MEDX - news) through Medarex`s wholly owned subsidiary GenPharm International, Inc. Genencor also announced today that it has licensed a key patent family from Pharming Group NV. Both of these developments are important for advancing the company`s i-mune(TM) mouse program.

The licenses from Medarex give Genencor the freedom to develop, generate and use mice with transplanted human cells for research and development of commercial non-antibody therapeutic products. The licensed Pharming patents cover the insertion of greater than 50 kb DNA into a mammalian cell or animal, which can be used to introduce human genes into a mouse, an important step in the development of Genencor`s i-mune transgenic mouse model.

``This is a very important step in the development of our i-mune mouse model,`` said Dr. Michael V. Arbige, senior vice president of technology for Genencor. ``This model, along with our predictive antigen system, the in vitro i-mune(TM) assay, will further expand our broad reaching immunology platform. Opportunities for this platform are expansive across all of our target markets, but they will certainly play a major role in our developments for the health care market.``

Genencor is currently developing a transgenic mouse model of the human immune system. Current models fail to develop normal immune systems when supplied with allogeneic (mismatched) mouse immune cells or human immune cells. To date, Genencor has developed a novel immuno-deficient mouse model that overcomes the genetic barriers associated with mismatched bone marrow transplantation. Comparable engraftment of human hematopoietic stem cells requires the addition of human factors that are best provided using transgenic methods. Genencor`s transgenic mouse model of the human immune system will provide an important tool for the modeling of human infectious diseases and autoimmune disorders, as well as other diseases affecting the immune system.

Genencor International is a global leader in the development of genetically based biotechnology products for the health care, agriculture and industrial chemicals markets. Genencor was established in 1982 as a joint venture between Genentech Inc. and Corning Incorporated. Since its founding, Genencor has grown to become a leading biotechnology company, with over $300 million in 1999 revenue, more than 250 biotechnology products in commerce, and over 3,000 owned and licensed patents and applications. Genencor, with more than 1,500 employees worldwide, has principal offices in Palo Alto, California; Rochester, New York; and Leiden, the Netherlands.

Except for the historical information contained herein, the matters discussed in this press release may contain forward-looking statements which involve risks and uncertainties, including significant fluctuations in product performance depending on factors such as a dependence on the efforts of third parties, a new and uncertain technology employed by Genencor and its uncertain application to new business ventures, dependence on intellectual property rights, the competitive nature of Genencor`s industry and risks of obsolescence of certain technology. Actual results may differ materially from those projected. Forward-looking statements represent the judgment of Genencor as of the date of this release. Genencor disclaims, however, any intent or obligation to update any forward-looking statements.

For More Information
Investors: Amy Giller, 650-846-7500
Media: Angie Blackwell, 716-256-5200
SOURCE: Genencor International, Inc.

Das dürfte Lizenzgebüren für Medarex bedeuten und zeugt von der Qualität ihrer Technik.

[lilabaer]

Na bitte, es geht doch. Momentan schon wieder über 100 und ich gleich im Gegensatz zu früher werden wir heute kurz vor Schluß keinen Abfall mehr sehen.

[Madman drummers]

War wohl leider nichts. Hoffen auf morgen. Und dann ab.

[IWA Japan]

jetzt seit doch net so ungeduldig

[IWA Japan]

dann kauft euch halt ABGx

[lilabaer]

Das war doch schon mal ein ganz guter Beginn heute. Momentan 3 im Plus. 105 ist heute vielleicht noch drin.

[lilabaer]

Tolle Woche: Wenn das so weitergeht, dann....naja träumen ist ja erlaubt. Aber so eine konstant gute Woche haben wir lange nicht mehr gesehen. Langsam scheint Medarex seine extrem Volatilität aufzugeben.
Solange die Richtung stimmt solls mir recht sein.